Michael G. Kauffman, M.D., Ph.D., CEO of EPIX Pharmaceuticals, Inc.,
Rings The NASDAQ Stock Market Closing Bell

Tuesday, August 22, 2006
at NASDAQ's MarketSite
in New York City.

EPIX Pharmaceuticals, Inc.

Michael G. Kauffman, M.D., Ph.D., CEO of EPIX Pharmaceuticals, Inc. (EPIX) presides over the closing bell to celebrate its merger with Predix Pharmaceuticals Holdings, Inc. As a result of the merger and reverse stock split, a "D" will be appended to EPIX's NASDAQ trading symbol for the next 20 days, after which time it is expected to continue to trade under the NASDAQ symbol "EPIX."
EPIX Pharmaceuticals is a late-stage biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products through the use of proprietary technology to better diagnose, treat and manage patients. The company has a blood-pool imaging agent approved and marketed in Europe (Vasovist(r)), and five internally-discovered drug candidates currently in clinical trials targeting conditions such as anxiety, depression, Alzheimer's disease, cardiovascular disease and obesity. EPIX also has collaborations with leading organizations, including Amgen, Cystic Fibrosis Foundation Therapeutics, and Schering AG, Germany. For more information about EPIX, please visit the company's website at www.epixpharma.com.

Reprints

Click for larger pictures of the NASDAQ MarketSite. Additional Photographs for 8/22/2006 Download Hi-Res Quality Photo of this NASDAQ Market Close - Pictured: Michael G. Kauffman, M.D., Ph.D., CEO of EPIX Pharmaceuticals, Inc. presides over the closing bell. These photos are Copyright 2006, The Nasdaq Stock Market Inc. and available for re-publication by the news media only. Any commercial use is strictly prohibited without the prior written consent of The Nasdaq Stock Market Inc. © Copyright 2006, The NASDAQ Stock Market, Inc. Reprinted with the permission of The Nasdaq Stock Market, Inc.